Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE and to a collection of information unless it contains a valid OMB control number. U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	estitute for form 1449A/PT	0			Complete if Kn wn
		_		Application Number	10/030,963
11	NFORMATIO	N DI	SCLOSURE	Filing Date	January 9, 2002
. S	STATEMENT	BY A	APPLICANT	First Named Inventor	Shayman et al.
				Art Unit	1614
	(use as many s	heets as	necessary)	Examiner Name	To be assigned
Sheet	1	of	3	Attorney Docket Number	30275/38151


			U.S. PA	TENT DOCUMENTS		
Fire-sizes	C'1-	Document Number	Publication Date	Name of Patenton as Applicant		Columns, Lines, ere Relevant
Examiner Initials*	Cite No. ¹	Number-Kind Code ² (if known)	MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Passa	ges or Relevant pres Appear
RR	A1	6,255,336	07-03-2001	Shayman et al.	510	1422
RR	A2	6,051,598	04-18-2000	Shayman et al.	514	1428
RR	А3	6,040,332	03-21-2000	Shayman et al.	514	428
RR	A4	6,030,995	02-29-2000	Shayman et al.	514	428
RR	A5	5,952,370	09-14-1999	Shayman et al.	514	428
RR	A6	5,945,442	08-31-1999	Shayman et al.	514	428
RV	A7	5,916,911	06-29-1999	Shayman et al.	514	428

		FOREI	GN PATENT	DOCUMENTS	-	
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant	
Initials*	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	T ⁶
R	B1	WO 97/10817	03-27-1997	WIPO		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
RT	C1	Abdel-Magid et al., "Metal-Assisted Aldol Condensation of Chiral A-Halogenated Imide Enolates: A Stereocontrolled Chiral Epoxide Synthesis," J. Am. Chem. Soc., 108:4595-4602 (1986).	
RR	C2	Abe et al., "Structural and Stereochemcial Studies of Potent Inhibitors of Glucosylceramide Synthase and Tumor Cell Growth," J. Lipid. Res., 36:611-621 (1995).	
RR	C3	Abe et al., "Improved Inhibitors of Glucosylceramide Synthesis," J. Biochem., 111:191-196 (1992).	
RR	C4	Abe et al., "Metabolic Effects of Short-Chain Ceramide and Glucosylceramide on Sphingolipids and Protein Kinase C," Eur. J. Biochem., 210:765-773 (1992).	
RR	C5	Abe et al., "Induction of Glucosylceramide Synthase by synthase Inhibitors and Ceramide," Biochim. Biophys. Acta, 1299:333-341 (1996).	
RP	C6	Alon et al., "Glycolipid Ligands for Selectins Support Leukocyte Tethering & Rolling Under Physiologic Flow Conditions," J. Immunol., 154:5356-5366 (1995).	
RE	C7	Ames, "Assay of Inorganic Phosphate, Total Phosphate and Phosphates," <i>Methods Enzymol.</i> , 8:115-118 (1966).	
RR	C8	Bielawska, A. et al., "Ceramide-Mediated Biology. Determination of Structural and Stereospecific Requirements Through the Use of N-Acyl-Phenylaminoalcohol Analogs," <i>J. Biol. Chem.</i> , 267:18493-18497 (1992).	
RR	C9	Bielawska, A. et al., "Modulation of Cell Growth and Differentiation by Ceramide," FEBS Letters, 307:211-214 (1992).	
RR	C10	Blobe, G. C. et al., "Regulation of PKC and Its Role in Cancer Biology," Cancer Metastasis Rev., 13:411-431 (1994).	
RR	C11	Brenkert, A. et al., "Synthesis of Galactosyl Ceramide and Glucosyl Ceramide by Rat Brain: Assay Procedures and Changes with Age," <i>Brain Res.</i> , 36:183-193 (1972).	
RR	C12	Carson, K. G. et al., "Studies on Morpholinosphingolipids: Potent Inhibitors of Glucosylceramide Synthase," <i>Tetrahedron Lett.</i> , 35:2659-2662 (1994).	
RN	C13	Evans, D. A. et al., "Stereoselective Aldol Condensations Via Boron Enolates," J. Am. Chem. Soc., 103:3099-3111 (1981).	_

		1	
Examiner Signature	Raynul	Date Considered	10-23-03





PTO/SB/08B (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sı	ubstitute for form 1449B/F	PTO		C mplete if Known		
				Application Number	10/030,963	
[]	VFORMATIC	ON DIS	CLOSURE	Filing Date	January 9, 2002	
9	STATEMENT	BY AF	PPLICANT	First Named Inventor	Shayman et al.	
				Group Art Unit	1614	
	(use as many	sheets as ne	cessary)	Examiner Name	To be assigned	
Sheet	2	of	3	Attorney Docket Number	30275/38151	

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	publisher, city and/or country where published.	T²
RR	C14	Felding-Habermann, B. et al., "A Ceramide Analog Inhibits T Cell Proliferative Response Through Inhibition of Glycosphingolipid Synthesis and Enhancement of N,N-Dimethylsphingosine Synthesis," <i>Biochemistry</i> , 29:6314-6322 (1990).	
RR	C15	Gatt, S. et al., "Assay of Enzymes of Lipid Metabolism With Colored and Fluorescent Derivatives of Natural Lipids," <i>Meth. Enzymol.</i> , 72:351-375 (1981).	
RR	C16	Hakomori, S. "New Directions in Cancer Therapy Based on Aberrant Expression of Glycosphingolipids: Anti-adhesion and Ortho-Signaling Therapy," <i>Cancer Cells</i> , 3:461-470 (1991).	
RK	C17	Hammett, L. P., In Physical Organic Chemistry, McGraw-Hill, New York (1940).	
KK.	C18	Hogberg, T. et al., "Theoretical and experimental methods in drug design applied on antipsychotic dopamine antagonists," in <u>Textbook of Drug Design and Development</u> pp. 55-91 (1991).	
PK	C19	Hospattankar, A. V. et al., "Changes in Liver Lipids After Administration of 2-Decanoylamino-3-Morpholinopropiophenone and Chlorpromazine," <i>Lipids</i> , 17:538-543 (1982).	
RP	C20	Inokuchi, J. et al., "Antitumor Activity in Mice of an Inhibitor of Glycosphingolipid Biosynthesis," Cancer Lett., 38:23-30(1987).	
ĸR	C21	Inokuchi, J. et al., "Inhibition of Experimental Metastasis of Murine Lewis Long Carcinoma by an Inhibitor of Glucosylceramide Synthase and its Possible Mechanism of Action," <i>Cancer Res.</i> , 50:6731-6737 (1990).	
RK	C22	Inokuchi, J. et al., "Preparation of the Active Isomer of 1-Phenyl-2-Decanoylamino-3-Morpholino-1-Propanol, Inhibitor of Glucocerebroside Synthetase," <i>J. Lipid Res.</i> , 28:565-571 (1987).	
RK	C23	Jaffrezou, J. et al., "Inhibition of Lysosomal Acid Sphingomyelinase by Agents which Reverse Multidrug Resistance," <i>Biochim. Biophys. Acta</i> , 1266:1-8 (1995).	
RR	C24	Kalen, A. et al., "Elevated Ceramide Levels in GH4C1 Cells Treated with Retinoic Acid," Biochim. Biophys. Acta, 1125:90-96 (1992).	
RR	C25	Kopaczyk, K. C. et al., "In Vivo Conversions of Cerebroside and Ceramide in Rat Brain," J. Lipid Res., 6:140-145 (1965).	
RK	C26	Lee, L. et al., "Improved Inhibitors of Glucosylceramide Synthase," J. Biol. Chem., 274(21):14662-669 (1999).	
RR	C27	Nakamura, K. et al., "Coomassie Brilliant Blue Staining of Lipids on Thin-Layer Plates," <i>Anal. Biochem.</i> , 142:406-41 (1984).	
RR	C28	Nicolaou, K. C. et al., "A Practical and Enantioselective Synthesis of Glycosphingolipids and Related Compounds. Total Synthesis of Globotriaosylceramide (Gb3)," <i>J. Am. Chem. Soc.</i> , 110:7910-7912 (1988).	
IER	C29	Preiss, J. E. et al., "Quantitative Measurement of SN-1,2-Diacylglycerols Present in Platelets, Hepatocytes, and Ras- and Sis-Transformed Normal Rat Kidney Cells," <i>J. Biol. Chem.</i> , 261:8597-8600 (1986).	
RR	C30	Radin N. S. et al., "Ultrasonic Baths as Substitutes for Shaking Incubator Baths," <i>Enzyme</i> , 45:67-70 (1991).	
RP	C31	Radin, N. S. et al., "Metabolic Effects of Inhibiting Glucosylceramide Synthesis with PDMP and Other Substances," In Advances in Lipid Research; Sphingolipids in Signaling, Part B., R. M. Bell et al., Ed. (Academic Press, San Diego) 28:183-213 (1993).	
RP	C32	Radin, N. S. et al., "Use of 1-Phenyl-2-Decanoylamino-3-Morpholino-1-Propanol (PDMP), an Inhibitor of Glucosylceramide Synthesis," In NeuroProtocols, A Companion to Methods in Neurosciences, S. K. Fisher et al., Ed., (Academic Press, San Diego) 3:145-155 (1993).	

Examiner Date Considered			·
Signature Considered	 PKanny	Date Considered	10-23-03

JUN 1 3 2003 TECH CENTER 1600/2900

PTO/SB/08B (10-01)
Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to Substitute for form 14498/PTO			Complete if Known		
				Application Number	10/030,963
II.	IFORMATION	1 DI	SCLOSURE	Filing Date	January 9, 2002
S	TATEMENT I	3Y A	APPLICANT	First Named Inventor	Shayman et al.
				Group Art Unit	1614
	(use as many sh	eets as	necessary)	Examiner Name	To be assigned
Sheet	3	of	3	Attorney Docket Number	30275/38151

JUN 1 2 2003

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	_
Examiner nitials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	-2
RN	C33	Rosenwald, A. G. et al., "Effects of a Sphingolipid Synthesis Inhibitor on Membrane Transport Through the Secretory Pathway," <i>Biochemistry</i> , 31:3581-3590 (1992).	
RR.	C34	Rosenwald, A. G. et al., "Effects of the Glycosphingolipid Synthesis Inhibitor, PDMP, on Lysosomes in Cultured Cells," <i>J. Lipid Res.</i> , 35:1232 (1994).	
RR.	C35	Shayman, J. A. et al., "Modulation of Renal Epithelial Cell Growth by Glucosylceramide: Association with Protein Kinase C, Sphingosine, and Diacylglyceride," <i>J. Biol. Chem.</i> , 266:22968-22974 (1991).	
RK	C36	Shayman, J. A. et al., "Glucosphingolipid Dependence of Hormone-stimulated Inositol Trisphophate Formation," <i>J. Biol. Chem.</i> , 265:12135-12138 (1990).	
KR.	C37	Shukla, A. et al., "Metabolism of D-[3H]PDMP, an Inhibitor of Glucosylceramide Synthesis, and the Synergistic Action of an Inhibitor of Microsomal Monooxygenase," <i>J. Lipid Res.</i> , 32:713-722 (1991).	
RR	C38	Shukla, G. S. et al., "Glucosylceramide Synthase of Mouse Kidney: Further Characterization and Improved Assay Method," Arch. <i>Biochem. Biophys.</i> , 283:372-378 (1990).	
RV	C39	Shukla G. et al., "Rapid Kidney Changes Resulting From Glycosphingolipid Depletion by Treatment with a Glucosyltransferase Inhibitor," <i>Biochim. Biophys. Acta</i> , 1083:101-108 (1991).	
1812	C40	Skehan, P. et al., "New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening," J. Natl. Cancer Inst., 82:1107-1112 (1990).	
RI?	C41	Strum, J. C. et al., "1-b-D-Arabinofuranosylcytosine Stimulates Ceramide and Diglyceride Formation in HL-60 Cells," <i>J. Biol Chem.</i> , 269:15493-15497 (1994).	
RR	C42	Svensson, M. et al., "Epithelial Glucosphingolipid Expression as a Determinant of Bacterial Adherence and Cytokine Production," <i>Infect. and Immun.</i> , 62:4404-4410 (1994).	
RR	C43	Tang, W. et al., "Phorbol Ester Inhibits 13-Cis-Retinoic Acid-induced Hydrolysis of Phosphatidylinositol 4,5-Bisphosphate in Cultured Murine Keratinocytes: a Possible Negative Feedback Via Protein Kinase C-Activation," <i>Cell Bioch. Funct.</i> , 9:183-191 (1991).	
KR	C44	Uemura, K. et al., "Effect of an Inhibitor of Glucosylceramide Synthesis on Cultured Rabbit Skin Fibroblasts," <i>J. Biochem.</i> , (Tokyo) 108:525-530 (1990).	
KK	C45	Vunnam, R. R. et al., "Analogs of Ceramide that Inhibit Glucocerebroside Synthetase in Mouse Brain," Chem. Phys. Lipids, 26:265-278 (1980).	
RN	C46	Zador, I. Z. et al., "A Role for Glycosphingolipid Accumulation in the Renal Hypertrophy of Streptozotocin-Induced Diabetes Mellitus," <i>J. Clin. Invest.</i> , 91:797-803 (1993).	
nv	C47	Ziche, M. et al., "Angiogenesis Can Be Stimulated or Repressed in In Vivo by a Change in GM3:GD3 Ganglioside Ratio," Lab. Invest., 67:711-715 (1992).	

		_
Examiner Signature	12 Kannal	Date Considered (6-23-03)